glp-1 drugs and dementia Can blockbuster weight loss also protect brain health? CKD Dementia Risk Reduced with

An important regulatory note: On December 22, 2025, the FDA approved Novo Nordisk's Wegovy tablet (oral semaglutide 25 mg) as the first oral GLP-1 receptor agonist for chronic weight management, with a national launch in January 2026

This would open the door to generic competition and personalized compounding, both of which could trigger a drop in prices

Cost and Insurance Coverage Out-of-pocket prices vary by drug, dose, and insurance, ranging from $349 to $1,600-plus per month

View price Many people take a supplement for Vitamin C for a general health boost, and it's something that's also taken if they have a Vitamin C deficiency